Sentences with word «pembrolizumab»
A Phase 1b / 2, Open - label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair - Proficient Colorectal Cancer
vicc.org
Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Dr Marcus Butler, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada, told ECCO2017 that 84 of the 1567 patients in the KEYNOTE - 001, 002 and 006 studies had advanced mucosal melanoma.
A Phase 1b / 2 Open - label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma
In a phase 1b clinical trial with 21 patients, researchers tested the safety and efficacy of combining the immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.
He said survival and response benefits for pembrolizumab were seen regardless of the levels of PD - L1 expression.
«KEYNOTE - 024 is the first phase III trial of pembrolizumab as first line treatment in patients with high PD - L1 expression, who represent 27 - 30 % of those with advanced NSCLC.»
In this case, the group used this humanized mouse model to test the FDA - approved immunotherapy pembrolizumab against the condition.
In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.
The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.
«I am treating people today with pembrolizumab alone and seeing some impressive outcomes,» said Dr. Rosalyn Juergens, oncologist and site lead investigator at Hamilton Health Sciences» Juravinski Cancer Centre, and associate professor of oncology at McMaster University.
The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 — blocking antibody pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.
«Pembrolizumab shows promise in treatment of mesothelioma.»
Up popped a trial at Hopkins, where doctors were testing a drug called pembrolizumab.
KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).
«Although only a small subset of women responded to the drug, within that subset pembrolizumab worked extremely well and responses were durable,» Adams adds.
In melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebo.
The secondary endpoint of overall survival was also significantly prolonged, and 80 % of patients on pembrolizumab were alive at six months compared to 72 % on chemotherapy (HR = 0.60).
Dr Butler said: «Our results show that patients benefited from pembrolizumab regardless of whether or not they had been pre-treated with ipilimumab.»
In Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBC.
Pembrolizumab blocks the action of the tumor - surface protein PD - 1, which many cancers use to hide themselves from immune system T cells.
Zakharia, who presented the data at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, reveals the overall response data from the trial, toxicity data, and compares the results to historical data of pembrolizumab monotherapy from KEYNOTE - 006, which included similar patients.
Dr. Ribas: Yes, it seems to be that the one from Merck [pembrolizumab] is in advanced approval process for melanoma, and the one from BMS [nivolumab] for lung cancer will probably follow.
On May 23, the Food and Drug Administration approved pembrolizumab for cancer patients with mismatch repair mutations for whom other drugs have failed.
The investigators found that pembrolizumab significantly improved the primary endpoint of progression - free survival by approximately four months compared to chemotherapy (10.3 months versus 6.0 months, hazard ratio [HR] 0.50).
In the first phase of MasterKey, T - VEC was injected into the tumors of 21 patients with advanced melanoma, followed by pembrolizumab immunotherapy.
In a second, late - breaking presentation, Dr Andrea Necchi, attending physician in the Department of Medical Oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, said results from the phase III KEYNOTE - 045 trial showed that treatment with pembrolizumab resulted in longer overall survival with fewer side - effects for patients with previously treated advanced bladder (urothelial) cancer compared with patients given chemotherapy.
For those taking pembrolizumab, there needs to be a certain threshold of PD - L1 expressed on the tumor for treatment, according to the FDA's label.
Now, patients with PD - L1 expression on at least half of their cancer cells can receive pembrolizumab prior to standard chemotherapy.
We are currently waiting for the results of several trials including EORTC 1325 which is investigating pembrolizumab, a PD - 1 checkpoint blocking antibody, compared to placebo in the adjuvant setting.»
«The objective overall response rate for the single agent pembrolizumab was up to 35 percent, but why shouldn't more patients respond?»
«Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression.»
Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.
By injecting T - VEC into the patients» tumors, even those that were located deeper in the body, the researchers were able to transform cold tumors into hot ones, which in turn allowed pembrolizumab to deliver a beneficial enhancement.
The goals of Cohort B, for which survival data are not yet complete, were, primarily, to prove pembrolizumab's safety and, secondarily, to explore its efficacy as a first - line treatment.
Checkpoint inhibitors like ipilimumab — which has been on the market since 2011 — nivolumab, and pembrolizumab stop tumor cells from stimulating the receptors.
We estimate that almost twice as many pembrolizumab responders will respond to the therapy for at least one year: 68 % versus 35 %.»
It represents a real advance in the second - line treatment of advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these patients.
Patients in the KEYNOTE trials received pembrolizumab intravenously at doses of 2 mg / kg or 10 mg / kg every three weeks, or 10 mg / kg every two weeks.
When this happens these patients can be offered immunotherapy drugs including pembrolizumab, nivolumab and ipilimumab.
Alley said there are already plans for trials that will test combination therapies, which will utilize pembrolizumab in conjunction with other treatments.
The study is funded by the biopharmaceutical company Merck & Co., which makes pembrolizumab, or Keytruda.
A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer
Although pembrolizumab has proven to be well tolerated and highly effective in shrinking or eliminating tumors, only a small proportion of patients respond to treatment.
Five weeks prior to initiating pembrolizumab, patients were given intralesional T - VEC injection at doses up to 4 mL per treatment (106 PFU / mL, then 108 PFU / mL every 2 weeks).
Treatment with the anti — PD - 1 antibody pembrolizumab yielded good long - term survival outcomes in a phase Ib trial of patients with advanced melanoma.
T - VEC plus pembrolizumab combo shows activity in advanced melanoma.
Reuters reports that about 30 % of people treated with pembrolizumab experience significant tumor shrinkage.